Phase II pilot trial of dose-dense docetaxel followed by doxorubicin plus cyclophosphamide (T-AC) given as adjuvant or neoadjuvant treatment for women with node positive or high-risk primary breast cancer

Trial Profile

Phase II pilot trial of dose-dense docetaxel followed by doxorubicin plus cyclophosphamide (T-AC) given as adjuvant or neoadjuvant treatment for women with node positive or high-risk primary breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs Cyclophosphamide; Docetaxel; Doxorubicin
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Aug 2008 Planned end date for this trial is now 1 Mar 2010 as reported by ClinicalTrials.gov
    • 16 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top